Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | The need for disease-modifying drugs in myelofibrosis

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, describes current challenges in myelofibrosis management. The approval of various JAK inhibitors have improved outcomes in patients and research into BET inhibitors will add to the current armamentarium. However, there is a demand for disease-modifying compounds that can improve overall survival (OS). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.